Brophy Michael Burkes sold $216K of NTRA

Brophy Michael Burkes (CHIEF FINANCIAL OFFICER) sold 795 shares of Natera, Inc. (NTRA) at an average of $271.74 ($267.99–$274.22, $0.22M total) across 2 trades over 2026-08-03 to 2026-08-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brophy Michael Burkes
Published Aug 6, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosed open-market sale reduces the insider’s direct holdings but does not, by itself, imply new information about Natera’s near-term fundamentals.

02

Market read

Traders may briefly watch for sentiment effects from insider selling, but the 10b5-1 framing lowers the signal strength.

03

What to watch

The article does not state whether other insiders sold/bought around the same window, nor does it provide total insider ownership changes beyond the post-transaction share count.

Relevance 3/10Novelty 3/10Timing: filed Aug 5, covering sales executed Aug 3 to Aug 4

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc., reported by the CFO.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CFO Brophy Michael Burkes sold about $216K of NTRA shares via a 10b5-1 plan on Aug 3 to Aug 4.

Expected impact

Likely limited near-term impact; any effect would be short-lived unless paired with other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction with stated 10b5-1 pre-arrangement, and the article provides no accompanying earnings, guidance, or operational developments.

Market effects

Minimal; insider sales under 10b5-1 typically do not reset sector expectations.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Natera, Inc.

    Company whose CFO insider sale is disclosed in the Form 4.

  • Brophy Michael Burkes

    Natera CFO who executed the reported open-market sales under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.